Defining utility values for patients with tardive dyskinesia

• Published in: Current medical research and opinion Vol. 38; no. 3; pp. 401 - 407
• Main Authors: Ayyagari, Rajeev, Goldschmidt, Debbie, Zhou, Mo, Ribalov, Rinat, Caroff, Stanley N., Leo, Sam
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 04.03.2022
• Subjects: Antipsychotic Agents - therapeutic use; Depressive Disorder, Major; Health Status; Humans; Quality of Life; Schizophrenia - drug therapy; social stigma; Tardive Dyskinesia; time tradeoff; utility values; Tardive dyskinesia; quality of life; time tradeoff; social stigma; utility values
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1080/03007995.2021.2022918

To measure health state preferences and estimate utility values for tardive dyskinesia (TD) from the perspective of the US general population, accounting for factors affecting quality of life (QOL). Participants from the general population were recruited and asked to watch and assess videos of professional actors simulating nine health states, including psychiatric disorders with/without TD and moderate-to-severe TD without any underlying disease. Time tradeoff (TTO) methods were used to elicit utility values, which ranged from −1 (worse than death) to +1 (perfect health) and represented individual preferences for avoiding specific health states associated with TD. Lower TTO utility values indicated individuals' willingness to give up more years of life to avoid living in each health state. Based on TTO responses (n = 157), mean ± standard deviation utility for TD alone was 0.59 ± 0.38. Mean utilities for schizophrenia with negative symptoms (without TD: 0.43; with TD: 0.29) and positive symptoms (without TD: 0.44; with TD: 0.30) were generally lower than those for bipolar disorder (without TD: 0.59; with TD: 0.46) and major depressive disorder (without TD: 0.60; with TD: 0.44). According to utility decrements associated with TD (0.13-0.16), respondents were willing to give up 1.3 to 1.6 years during a 10-year lifespan to avoid living with TD. Utility decrements for TD in this study were slightly larger than previously reported values, potentially due to incorporation of QOL and social consequences in TD health state descriptions. An important limitation of this analysis is that participants' willingness to trade future years of healthy life may not indicate actual willingness to accept the life decrement. These findings can be leveraged to improve cost-effectiveness analyses used to assess the value of treatments for TD.